Dst Systems Fund News

Buy DST

*Your capital is at risk

$83.99

+0 (+0%)

At Close: May 31, 2018

Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®

05:00pm, Saturday, 06'th Jun 2026

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinol

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by